Defunct Company
Total Trials
17
As Lead Sponsor
14
As Collaborator
3
Total Enrollment
1,448
NCT00627120
Phase I Safety and Pharmacokinetic Study of VGX-1027 in Healthy Subjects
Phase: Phase 1
Role: Collaborator
Start: Feb 29, 2008
Completion: Not specified
NCT00760396
Multiple-Dose Study of VGX-1027 in Healthy Subjects
Start: Sep 30, 2008
Completion: Apr 30, 2009
NCT01184976
Study Of VGX-3400, H5N1 Avian Flu Virus Plasmid DNA With Electroporation Device In Healthy Adult Males
Role: Lead Sponsor
Start: Aug 31, 2010
Completion: Apr 30, 2012
NCT02027116
Phase I Trial to Evaluate the Safety, Tolerability and Immunogenicity of VGX-6150 for Second-line Therapy of Chronic Hepatitis C Infection
Start: Jan 31, 2014
Completion: Jul 31, 2017
NCT02464670
Open-Label Study of INO-4212 With or Without INO-9012, Administered IM or ID Followed by Electroporation in Healthy Volunteers
Start: May 31, 2015
Completion: May 24, 2018
NCT02670187
Phase I, Open Label Dose Ranging Safety Study of GLS-5300 in Healthy Volunteers
Start: Feb 29, 2016
Completion: Sep 30, 2017
NCT02809443
GLS-5700 in Dengue Virus-Naïve Adults
Start: Jul 31, 2016
Completion: Dec 31, 2017
NCT02887482
GLS-5700 in Dengue Virus Seropositive Adults
Start: Aug 31, 2016
Completion: Jun 30, 2018
NCT03721718
Evaluate the Safety, Tolerability and Immunogenicity Study of GLS-5300 in Healthy Volunteers
Phase: Phase 1/2
Start: Aug 28, 2018
Completion: Apr 22, 2020
NCT03674125
Evaluation of Safety, Tolerability, and Immunogenicity Study of GLS-6150 in Healthy Volunteers and in Persons Previously Treated for Hepatitis C Virus Infection
Start: Sep 4, 2018
Completion: May 4, 2020
NCT04408183
GLS-1200 Topical Nasal Spray to Prevent SARS-CoV-2 Infection (COVID-19)
Phase: Phase 2
Start: Jun 10, 2020
Completion: Jan 10, 2023
NCT04673149
GLS-5310 Vaccine for the Prevention of SARS-CoV-2 (COVID-19)
Start: Dec 31, 2020
Completion: May 10, 2023
NCT04590547
GLS-1027 for the Prevention of Severe Pneumonitis Caused by SARS-CoV-2 Infection (COVID-19)
Start: May 7, 2021
Completion: Jul 24, 2023
NCT05085639
GLS-5310 Vaccine in Healthy Volunteers for the Prevention of SARS-CoV-2 (COVID-19)
Start: Nov 30, 2021
Completion: Dec 31, 2022
NCT05182567
GLS-5310 Vaccine in Healthy Volunteers as a Booster for SARS-CoV-2 (COVID-19)
Start: May 23, 2022
Completion: Dec 31, 2023
NCT05243329
Investigating the Therapeutic Effects of Psilocybin in Treatment-Resistant Post-Traumatic Stress Disorder
Start: Oct 3, 2022
Completion: Dec 30, 2023
NCT04060316
GLS-1200 Topical Nasal Spray to Prevent Sinusitis After Endoscopic Sinus Surgery
Start: Dec 31, 2023
Completion: Sep 30, 2024